Update shared on 01 Nov 2025
Fair value Increased 0.90%Analysts have slightly raised their price target for Agilent Technologies from $148.57 to $149.90, citing stable fundamentals and a modest valuation adjustment.
What's in the News
- Adam S. Elinoff appointed Chief Financial Officer, effective November 17, 2025, following his executive career at Amgen. (Executive Changes, CFO)
- Launch of the Insight Series Alarm Resolution Systems for airport security, featuring advanced liquid explosive detection and adaptability for evolving global regulations. (Product-Related Announcements)
- Partnership with Lunit to develop AI-powered companion diagnostic solutions aimed at advancing precision oncology and translational medicine. (Strategic Alliances)
- FDA approval received for the MMR IHC Panel pharmDx (Dako Omnis) as a companion diagnostic test for colorectal cancer patients eligible for immunotherapy. (Product-Related Announcements)
- Earnings guidance raised for full fiscal year 2025, with revenue outlook increased by $150 million at the midpoint. (Corporate Guidance, Raised)
Valuation Changes
- Fair Value Estimate has risen slightly from $148.57 to $149.90 per share.
- Discount Rate remains stable, with a marginal increase from 7.44% to 7.44%.
- Revenue Growth projection is unchanged at roughly 5.92%.
- Net Profit Margin expectation is steady, holding at about 22.44%.
- Future P/E Ratio has increased modestly from 28.20x to 28.46x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.